drugset / Trial / NCT00134719

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

NCT00134719

Phase 2 Completed 1104 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

This study is evaluating the safety and immunogenicity of Hib-MenCY-TT vaccine compared to control groups receiving licensed Hib or MenC conjugate vaccines, each administered at 2, 4, 6, and 12 to 15 months of age. Co-administration with live, attenuated measles, mumps, and rubella combination vaccine; and with live, attenuated varicella vaccine will be assessed with administration of the booster dose. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, September 2007.

Timeline

Start
2005-04-11
Primary completion
2006-07-24
Completion
2007-02-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator ActHIB Vaccine Intramuscular
Comparator HAEMOPHILUS INFLUENZAE TYPE B CAPSULAR POLYSACCHARIDE MENINGOCOCCAL OUTER MEMBRANE PROTEIN CONJUGATE ANTIGEN Vaccine Intramuscular
Subject Menhibrix Vaccine Intramuscular
Comparator Meningitec Vaccine Intramuscular
Background M-M-R II Vaccine Subcutaneous
Background Pediarix Vaccine Intramuscular
Background Prevnar 13 Vaccine Intramuscular
Background Varivax Vaccine Subcutaneous